https://biospectrumindia.com/rssfeed/states/odisha odisha https://biospectrumindia.com/news/106/28541/neuberg-diagnostics-prolife-diagnostics-announce-strategic-jv-to-expand-advanced-diagnostics-in-odisha.html https://biospectrumindia.com/news/106/28541/neuberg-diagnostics-prolife-diagnostics-announce-strategic-jv-to-expand-advanced-diagnostics-in-odisha.html Fri, 25 Sep 2026 17:20:42 +0530 Neuberg Diagnostics has entered into a strategic joint venture (JV) with Bhubaneswar-based ProLife Diagnostics to expand access to high-quality, affordable and advanced diagnostic services across Odisha. The new venture, Neuberg ProLife, will combine Neuberg’s pan-India scale, advanced diagnostic capabilities, high-end technology, AI-enabled IT platforms and quality systems with ProLife’s established reputation, local presence and deep understanding of Odisha’s healthcare ecosystem. Neuberg ProLife will offer a comprehensive portfolio spanning routine and specialised pathology, radiology, preventive wellness and advanced diagnostics, including genomics, metabolomics, proteomics, digital pathology and AI-enabled advanced radiology. Dr GSK Velu, Chairman and Managing Director, Neuberg Diagnostics said “Odisha is an important market in Neuberg’s pan-India expansion journey, with significant potential to improve access to quality and advanced diagnostics beyond the major urban centres. Through Neuberg ProLife, we are bringing together Neuberg’s technology, advanced diagnostic expertise and national scale with ProLife’s strong local presence and understanding of Odisha. Our vision is to build a future-ready diagnostic network focused on accessibility, affordability, early detection and preventive healthcare.” As part of its expansion strategy, Neuberg ProLife plans to establish 10 Integrated Diagnostics and Wellness Centres across Bhubaneswar, Cuttack, Rourkela, Berhampur, Sambalpur, Puri, Balasore, Bhadrak, Baripada and Jharsuguda. These centres will be supported by more than 100 satellite laboratories and sample collection centres across Odisha within the next two years. The hub-and-spoke network will enable patients across Tier 2, Tier 3 and emerging markets to access routine and specialised diagnostic services closer to home, reducing the need to travel to larger cities for advanced investigations. ]]> https://biospectrumindia.com/news/106/28167/nit-rourkela-secures-patent-for-eco-friendly-film-for-medical-products.html https://biospectrumindia.com/news/106/28167/nit-rourkela-secures-patent-for-eco-friendly-film-for-medical-products.html Tue, 21 Jul 2026 13:29:48 +0530 Researchers from the Department of Biotechnology and Medical Engineering at National Institute of Technology (NIT) Rourkela have created a new biodegradable composite film to potentially replace commonly used plastic materials in the healthcare sector. The developed innovation addresses the issue of non-biodegradable medical plastics disposal while meeting the market demand for sustainable biomaterials. The research team including Dr Angana Sarkar, Associate Professor, along with her research graduate Dr Pritam Bajirao from the Department of Biotechnology and Medical Engineering, NIT Rourkela, have secured a patent titled, "Biodegradable and Antimicrobial Bio-composite Film and Process for Preparing Thereof," for the developed innovation. Healthcare products such as wound dressings and bandages, are usually made using petroleum-based non-biodegradable plastics. The waste from these products resulting in environmental pollution. Although bioplastics such as polyhydroxyalkanoates (PHAs) offer a potential alternative, their large-scale adoption is limited due to their brittleness and slow degradation capabilities. To address these challenges, researchers from NIT Rourkela have created a material using a natural bioplastic produced by bacteria that grows on sugarcane molasses. To make the developed bio material mechanically strong and flexible, naturally extracted neem oil was mixed with the composite. This unique process resulted in development of a material that can serve as an alternative to plastic-based products used in the medical field. The technology can be used in a variety of healthcare-based products such as antimicrobial films, coatings, and sustainable healthcare products, as well as plastic-free bandages and wound dressings. The estimated production cost of the developed bio-composite film is Rs 14.33 for a 44.18 cm square (approx.) indicating strong potential for economical scale-up. ]]> https://biospectrumindia.com/news/106/28069/fortis-healthcare-signs-agreement-with-dion-group-for-300-bed-multi-specialty-hospital-in-cuttack.html https://biospectrumindia.com/news/106/28069/fortis-healthcare-signs-agreement-with-dion-group-for-300-bed-multi-specialty-hospital-in-cuttack.html Sat, 04 Jul 2026 08:32:24 +0530 Fortis Healthcare has signed an Operations and Management (O&M) agreement with Dion Group, one of Odisha's leading real estate and infrastructure development groups, for a 300-bed greenfield multi-specialty hospital to be developed at Dion Riverside Township, Trishulia in Cuttack, Odisha. Headquartered in Bhubaneswar, Dion Group has established a strong presence in the state through landmark residential, commercial and integrated township developments and is currently expanding its footprint across hospitality and healthcare infrastructure. Once operational, the facility will serve as a major tertiary care destination for Odisha and neighbouring regions, bringing advanced clinical expertise, cutting-edge medical technology, and globally benchmarked healthcare services closer to patients. Strategically located within the rapidly developing Cuttack-Bhubaneswar corridor, the hospital is envisioned as a Centre of Excellence for multiple specialties and will significantly strengthen access to advanced healthcare across Eastern India. The facility will offer comprehensive tertiary and quaternary care services supported by advanced diagnostics, critical care infrastructure, and specialised clinical programmes. The collaboration marks Fortis Healthcare's first major presence in Odisha and forms part of the company's broader strategy to expand access to quality healthcare across the country through a combination of brownfield expansion and inorganic growth initiatives, including operating and management agreements and asset-light growth models. The proposed hospital is expected to contribute significantly to the region's healthcare ecosystem by enhancing access to specialised treatment, reducing the need for patients to travel outside the state for complex medical care, and creating a robust platform for advanced clinical services, medical talent, and healthcare innovation. ]]> https://biospectrumindia.com/news/106/28049/nit-rourkela-engineers-smart-bandage-for-advanced-wound-care.html https://biospectrumindia.com/news/106/28049/nit-rourkela-engineers-smart-bandage-for-advanced-wound-care.html Tue, 30 Jun 2026 15:56:38 +0530 Researchers at the National Institute of Technology Rourkela (NIT Rourkela) have developed a smart wound dressing that prevents infections, minimises pain during removal, and promotes faster healing. In cases of injuries that require repeated dressing changes, patients usually suffer from the trauma and discomfort associated with them. The innovative wound dressing developed by Prof. Prasoon Kumar, Assistant Professor, Department of Biotechnology and Medical Engineering, addresses this under-recognised challenge. Due to its affordability, absorbency, and ease of usage, cotton gauze bandage is most commonly used for wound dressing. It is widely used to absorb blood and wound exudates and ointment applications. However, these conventional dressings are not capable of preventing infections or managing discomfort. Another limitation of the traditional cotton gauze is that it sticks to the wound surface and damages newly formed tissue when dressing is changed. Additionally, it also increases the susceptibility to infections. To address these limitations, NIT Rourkela researchers have developed a smart cotton gauze dressing that integrates chitosan-coated cotton gauze with an electrospun nanofibrous layer. This layer is filled with curcumin, a natural compound known for its antimicrobial properties. Placed between the wound and gauze, this layer minimises adhesive’s direct contact with the wound thereby reducing the risk of tissue damage during gauze removal. These curcumin-filled nanofibers slowly release the medication onto the wound and maintain sustained drug delivery. This approach helps maintain a sterile wound environment while reducing dependence on repeated gauze changes and additional medications. As the next step, the research team plans to file a patent for the developed technology and explore potential industry collaboration opportunities for clinical trials. Speaking about the cost-effectiveness of the developed wound dressing Prof. Kumar said, “Cotton Gauze Bandage Roll (10 cm × 4 m) costs around Rs 30 and our advanced smart bandage of similar size will cost around Rs 50-60 when fabricated at a commercial scale” ]]> https://biospectrumindia.com/news/106/27853/nit-rourkela-patents-ai-enabled-microscopy-tech-for-healthcare-diagnostic-solutions.html https://biospectrumindia.com/news/106/27853/nit-rourkela-patents-ai-enabled-microscopy-tech-for-healthcare-diagnostic-solutions.html Tue, 26 May 2026 16:39:51 +0530 Researchers from the Department of Biotechnology and Medical Engineering at National Institute of Technology (NIT) Rourkela have developed an AI-enabled autofocusing technology that can improve microscopic imaging for biomedical diagnostic applications. The technology is capable of producing rapid, accurate, and repeatable results with minimal human intervention. Developed in collaboration with Glowvista Instruments, a startup incubated at NIT Rourkela’s Incubator centre (FTBI), the research team has secured a patent titled, “A Method for Autofocusing in Optofluidic Microsystems and Processes” for the technology.     Developed at a cost of Rs 1.20 lakh, in lab-scale testing, the system showed accurate results in detecting Acute Lymphoblastic Leukemia (Blood Cancer), malaria, and Complete Blood Cells counts through blood cell classification (5-class and 7-class categorisation). Speaking about the developed technology, Dr Earu Banoth, Assistant Professor, Department of Biotechnology and Medical Engineering, NIT Rourkela, and Founder & Director (Non-Executive) of Glowvista Instruments said, “Our target is to develop a simple handheld system that should work as effectively as imported automated microscopy technology with precise information. Further, the system should be extended for various applications, unlike Flow Cytometers and Imaging Flow Cytometers.” The system has been developed with research grants from the Anusandhan National Research Foundation (ANRF), Department of Science and Technology (DST), and Department of Biotechnology (DBT), Government of India. The developed technology has potential applications in Biomedical diagnostics and disease detection; Digital pathology and tissue imaging; AI-assisted microscopy and automated imaging; Point-of-care healthcare devices; Microfluidic analysis and biofluid monitoring; Biomedical and Life sciences research; Smart laboratory automation; Portable and remote diagnostic systems. Speaking about the next steps of this research, Prof. Banoth said, “We are extending our work to develop complete ground truth data as well as scale up the work for deployment at various locations for field testing and to obtain feedback from diagnostic centres and research laboratories. The data will be used for further approvals towards developing a market-ready product, and we look forward to its market launch. At present, we are looking for funding support from both the research and startup sides to scale up the work.” ]]> https://biospectrumindia.com/news/106/27773/odisha-health-minister-inaugurates-vedanta-lanjigarhs-first-of-its-kind-telemedicine-facility.html https://biospectrumindia.com/news/106/27773/odisha-health-minister-inaugurates-vedanta-lanjigarhs-first-of-its-kind-telemedicine-facility.html Thu, 07 May 2026 22:11:38 +0530 Dr Mukesh Mahaling, Minister of Health & Family Welfare, Government of Odisha, inaugurated Vedanta Aluminium’s first-of-its-kind 24x7 Telemedicine Facility in Lanjigarh, Kalahandi district, launched in partnership with Tata 1mg through a virtual event. The initiative marks a major step towards strengthening healthcare access in Kalahandi by bringing timely specialist medical consultation closer to communities across remote villages, employees, families, business partners, etc. A dedicated Telemedicine Room has also been established at Vedanta Lanjigarh Hospital for assisted consultations. In addition, through the Tata 1mg App, beneficiaries can access free audio and video consultations with nearly 30 specialist and super-specialist doctors, reducing the need for long-distance travel for medical guidance. The service is expected to benefit more than 70,000 people across nearly 70 remote villages in Kalahandi and adjoining regions. Speaking on the occasion, Dr Mukesh Mahaling, said, “Vedanta’s 24x7 telemedicine facility is a meaningful step towards improving healthcare access for communities in Kalahandi, especially in remote tribal and rural areas where timely medical consultation can make a significant difference. Vedanta’s broader work in healthcare, education, women empowerment and livelihoods reflects how responsible industry can support the state’s development priorities. Continued collaboration between government, industry and communities will be important for ensuring inclusive and balanced development across Odisha.” Vedanta’s diverse community projects such as Project Aarogya is bringing healthcare closer to remote villages through preventive care, health camps and medical outreach, while Project Sakhi is helping women build skills, confidence and income opportunities through entrepreneurship and self-help groups. Around Kalahandi and the Raigarh region, multiple interventions are helping build healthier, more skilled and self-reliant communities. Across Odisha, Vedanta Aluminium’s community programmes have positively impacted more than 10 lakh people, supported by over Rs 500 crore invested in social development initiatives over the years.   ]]> https://biospectrumindia.com/news/106/27627/max-healthcare-forays-in-bhubaneshwar-to-acquire-controlling-stake-in-kalinga-hospital-for-rs-300-cr.html https://biospectrumindia.com/news/106/27627/max-healthcare-forays-in-bhubaneshwar-to-acquire-controlling-stake-in-kalinga-hospital-for-rs-300-cr.html Wed, 08 Apr 2026 00:00:00 +0530 Max Healthcare Institute has entered into a share purchase agreement to acquire controlling stake in Kalinga Hospital Limited (KHL) from Hospital Corporation of Orissa Inc. Under the agreement, MHIL shall acquire 58.4% stake in KHL at an equity value of Rs 300 crore (including control premium). The 250 bed NABH accredited hospital is built on a ~10-acre land parcel at Maitri Vihar, Bhubaneswar, a prime location in the heart of the city. Spread over ~2,60,000 sq. ft., the hospital provides multidisciplinary care across major specialties, including Neurology, Cardiology, Orthopaedics, Gastroenterology, Renal Sciences and Oncology; backed by diagnostics and equipped with a 128-slice CT scanner, 1.5T MRI, and Cath Lab, etc.Bhubaneswar has a well-developed healthcare eco-system with large footprint of public,  private hospitals and multiple medical colleges, positioning the city as a preferred healthcare provider for patients from across Odisha and neighbouring states of West Bengal, Jharkhand and Chhattisgarh. This acquisition will strengthen MHIL’s network and expand its footprint in Eastern India. Commenting on the transaction, Abhay Soi, Chairman and Managing Director, Max Healthcare Institute Ltd., said, “Happy to announce our foray into Bhubaneshwar, an extremely attractive market, through the acquisition of a very well located and reputable hospital with significant operational upside and brownfield potential. Such prime opportunities are extremely rare. This acquisition allows us to strengthen our footprint and enables us to extend high quality healthcare services to a fast-growing region.”The transaction shall be consummated upon completion of conditions precedent as stipulated in the share purchase agreement. ]]> https://biospectrumindia.com/news/106/27586/nit-rourkela-develops-multi-sensor-ai-system-for-accurate-sleep-posture-detection.html https://biospectrumindia.com/news/106/27586/nit-rourkela-develops-multi-sensor-ai-system-for-accurate-sleep-posture-detection.html Mon, 30 Mar 2026 00:00:00 +0530 Researchers at the National Institute of Technology (NIT) Rourkela have developed an artificial intelligence (AI)-enabled system that can track human sleep postures. This is useful in healthcare settings, as it provides a non-intrusive way to monitor patients while maintaining their privacy, even when they are covered with a blanket. Studies from around the world show that poor sleeping posture can cause long-term health conditions by putting sustained, uneven pressure on the spine, joints, and nerves for hours at a time. Currently, patient posture monitoring is mostly done manually, which can be inconsistent and prone to human error. Although wearable sensors can be an option, but they are uncomfortable and costly for the end users. Additionally, some systems use cameras, however they can be limited by factors including insufficient lighting, obstructions such as bed covers, and privacy issues. To address these limitations, researchers have developed an AI-based system that uses three types of sensors: An imaging sensor in the long-wave infrared spectrum that captures and uses body heat to track sleep postures, and does so without using visual data, even if the subject is covered by a blanket; A depth sensor that captures the shape and posture of a person; A pressure sensor that assesses how the weight is distributed on the bed. To process the data from these sensors, the team developed a generative AI model to represent the human body, and a graph-based neural network to classify the various postures of body joints. By combining heat-based imaging, body shape data, and pressure information, the system can deliver accurate results. Lab experiments show that this no-contact model achieves around 98% accuracy, making it reliable for real-world use. To be used as an integrated module with multi-modal imaging systems, the approximate cost of the developed technology will be Rs 30,000, with scope for further reduction with mass-scale development. As a next step, the research team plans to extend the usage of this technology for identification of specific incorrect sleep posture-related health issues and other diseases.   ]]> https://biospectrumindia.com/news/106/27453/babycue-receives-govt-support-to-develop-rapid-diagnostic-equipment-for-childhood-diarrhoea.html https://biospectrumindia.com/news/106/27453/babycue-receives-govt-support-to-develop-rapid-diagnostic-equipment-for-childhood-diarrhoea.html Mon, 09 Mar 2026 00:00:00 +0530 The Technology Development Board of the Department of Science and Technology, Government of India, has provided financial assistance to Cuttack-based startup BabyCue for a project to develop a disposable paper analytical device for rapid detection of childhood diarrhoea. The project focuses on commercialising indigenous rapid diagnostic kits, which have been designed to detect the difference between bacterial and non-bacterial diarrhoea in children in a timely manner. The proposed product, DyCue Diagnostic Kit is an important indigenous innovation combining biotechnology and materials science to tackle the widespread problem of diarrhoea in the country. The kit is designed as a quick, non-harmless and cost-effective diagnostic tool that can also be used in rural health centres and temporary diagnostic centres. The device is based on lateral flow assay (LFA) technology, which rapidly identifies disease using disease-specific fecal biomarkers. The system uses gold nanoparticle-based colorimetric detection, allowing results to be visually understood without the need for specialised laboratory equipment. The use of proprietary biomarkers and specially designed reagents ensures high sensitivity and specificity, making it possible to make a reliable distinction between bacterial and non-bacterial infections. Proprietary biomarkers are patented, biological indicators (molecules, genes, or imaging characteristics) that are made by specialty pharmaceutical, diagnostic, or biotech companies to detect diseases, predict treatment efficacy, or drug efficacy.   The technology has been developed in collaboration with National Institute of Pharmaceutical Education and Research, Hyderabad and has been clinically validated at ESIC Hospital, Hyderabad.  Technology Development Board will help the company to accelerate product development, increase manufacturing capacity and deploy this diagnostic solution widely for the benefit of healthcare providers and patients. ]]> https://biospectrumindia.com/news/106/26810/nit-rourkela-pioneers-green-alternative-to-fight-antibiotic-resistance.html https://biospectrumindia.com/news/106/26810/nit-rourkela-pioneers-green-alternative-to-fight-antibiotic-resistance.html Wed, 15 Oct 2025 00:00:00 +0530 Researchers at the National Institute of Technology (NIT) Rourkela have used extracts from medicinal plants to produce potent antibacterial agents that are environmentally safe and effective. The research addresses the problem of antimicrobial resistance. The overuse of traditional antibiotics has resulted in the rise of “superbugs” that have become resistant to these treatments. All around the world, scientists are seeking alternative methods to fight these superbugs.  One promising class of materials that has been studied is Zinc oxide nanoparticles, materials so tiny that tens of thousands of them could fit across the width of a human hair. These tiny particles damage the bacterial cells and disrupt their normal functions. Electrically charged Zinc ions damage the cell membrane by producing reactive molecules that stress and kill the bacteria, as well as by blocking the cell’s vital processes. Conventional synthesis of these nanoparticles involves the use of harsh chemicals that can be toxic to humans and/or the environment. To address this NIT Rourkela researchers have used an eco-friendly approach to producing the Zinc oxide nanoparticles. Instead of using harsh chemicals, the researchers used extracts from leaves and petals of Marigold, Mango, and Eucalyptus to reduce zinc salts into zinc oxide nanocrystals with adsorbed phytocompounds from the extracts. Highlighting the importance of the research, Prof. Suman Jha, Associate Professor. Department of Life Science, NIT Rourkela, said, “The green-synthesized zinc oxide nanoparticles with phyto-corona, as a sustainable and effective antimicrobial platform, offer a promising solution to combat antimicrobial resistance while leveraging the medicinal properties of surface-adsorbed plant-derived phytocompounds. This work is a step toward developing a new generation of green nanomaterials that can support sustainable healthcare systems. Our vision is to develop scalable, affordable, and environmentally safe antimicrobial materials that can be integrated into healthcare, sanitation, and food preservation applications. By harnessing India’s rich biodiversity and indigenous plant resources, we aim to create self-reliant innovations that contribute meaningfully to global health and sustainability goals.”  ]]> https://biospectrumindia.com/news/106/26544/odisha-launches-ground-breaking-marine-biotechnology-initiative-ombric-.html https://biospectrumindia.com/news/106/26544/odisha-launches-ground-breaking-marine-biotechnology-initiative-ombric-.html Tue, 19 Aug 2025 00:00:00 +0530 Chief Minister of Odisha Mohan Charan Majhi has launched the Odisha Marine Biotechnology Research & Innovation Corridor or OMBRIC. Recognising the immense potential of the 574 km long coastline packed with unexplored rich marine bioresources, the Science & Technology Department, Government of Odisha, has conceptualised and initiated the Odisha Marine Biotechnology Research & Innovation Corridor (OMBRIC), a pioneering initiative aimed at transforming and positioning Odisha into a global leader in marine biotechnology and Blue Economy development in future. With a budget of Rs 50 crore over five years, this initiative reflects the Government of Odisha’s unwavering belief in the power of science to shape a sustainable future. To ensure targeted and high-impact execution, six premier institutions in Odisha have been selected as hubs of OMBRIC based on their scientific expertise and regional relevance. These institutions will lead various components of OMBRIC with specific objectives aligned with their areas of expertise and need of the state: IIT Bhubaneswar – Comprehensive mapping and monitoring of Odisha’s coastal marine bioresources using satellite images, GIS, remote sensing, drone survey etc. and assessment of coastal ecosystem health and capacity building. NIT Rourkela – Cultivation of unculturable marine microorganisms and extraction of novel bioactive compounds (Enzymes, Pigments, Antibiotics etc.) with pharmaceutical and industrial applications. IISER Berhampur – Novel Gene discovery, characterisation and structural elucidation of marine bioactive compounds and upscaling of high valued marine products through chemical engineering. ILS Bhubaneswar – Establishment of a Marine Microbial Biorepository, to publish Odisha Marine Bio Resource Atlas with Genetic Footprint and to promote innovation, start-up activities in blue technology. Berhampur University – Marine biodiversity mapping and metabolite characterisation of Marine algae, seaweeds, fishes and other sea animals. Fakir Mohan University – Commercial breeding technology and scalable protocol for breeding of Indian horseshoe crabs and translational applications of extracted bioactive compounds. Crucially, OMBRIC is designed to translate research into tangible economic outcomes. Through IP generation, incubation support, and entrepreneurial mentoring, research findings will evolve into market-ready products, fostering the growth of marine biotech startups and enterprises. This “lab-to-market” pipeline ensures a sustainable ecosystem for innovation-driven marine industrialisation in Odisha. In addition to advancing research, OMBRIC places strong emphasis on community engagement and social impact. The initiative seeks to involve coastal populations through training, education, and participatory conservation, thereby fostering marine stewardship while improving local livelihoods and social equity. Further, a Memorandum of Understanding (MoU) has been signed between the Department of Science and Technology, and Indian Institute of Management (IIM), Sambalpur in the presence of Krushna Chandra Patra, Minister of Science and Technology, Food Supply and Consumer Welfare, Odisha and Chithra Arumugam, Principal Secretary, Science & Technology Department. The MoU was signed by Puja Mishra, Addl. Secretary Cum Director Biotechnology and Prof. Mahadeo Jaiswal, Director, IIM-Sambalpur.    ]]> https://biospectrumindia.com/news/106/26530/nit-rourkela-decodes-sugar-molecules-and-bone-protein-complex-to-boost-bone-regeneration-technology.html https://biospectrumindia.com/news/106/26530/nit-rourkela-decodes-sugar-molecules-and-bone-protein-complex-to-boost-bone-regeneration-technology.html Wed, 13 Aug 2025 00:00:00 +0530 Scientists at National Institute of Technology (NIT) Rourkela, Odisha have uncovered how natural sugar-like molecules in the human body can alter the behaviour of Bone Morphogenetic Protrin-2 (BMP-2), a protein responsible for bone formation and repair. Published in the journal Biochemistry, the findings of this research can be used for advanced treatments in bone and cartilage regeneration, improved implants, and more effective protein-based medicines. BMP-2 plays a crucial role in forming bones and cartilage, healing injuries, and guiding stem cells to become bone-forming cells. However, in the human body, this protein interacts with different Glycosaminoglycans (GAGs), special sugar-like molecules found in connective tissues and joint fluids. The NIT Rourkela research team investigated how these different GAGs affect BMP-2 when it is exposed to “stress” in the form of urea-induced chemical denaturation. The team observed that BMP-2 unfolded faster in the presence of Sulfated Hyaluronic Acid (SHA), a type of GAG, compared to regular Hyaluronic Acid or without additives. The researchers found that SHA binds directly to BMP-2 protein, gently altering its structure and making it unfold in a more controlled manner. Speaking about the findings and potential real-world impact of this research, Prof. Harekrushna Sahoo, said. “BMP-2 is a critical protein in humans that plays a fundamental role in osteogenesis and bone regeneration, residing within the glycosaminoglycan-rich extracellular matrix environment of bone tissue. Our study reveals how specific GAG–BMP-2 interactions influence unfolding dynamics and structural stability. These insights allow scaffold designs to actively preserve BMP-2’s functional conformation, prolong bioactivity, lower dosage needs, and reduce side effects. Furthermore, the work offers a mechanistic basis for tailoring GAG functional group modifications to modulate protein structure and activity, guiding next-generation pharmaceutical formulation.”   ]]> https://biospectrumindia.com/news/106/26128/curebay-raises-21-m-to-lead-equitable-healthcare-movement.html https://biospectrumindia.com/news/106/26128/curebay-raises-21-m-to-lead-equitable-healthcare-movement.html Tue, 20 May 2025 00:00:00 +0530 Bhubaneshwar-based startup CureBay, a tech-first hybrid healthcare platform, has raised $21 million in its Series B funding round led by Bertelsmann India Investments. The round saw participation from existing investor Elevar Equity, reaffirming its commitment to Curebay’s mission along with British International Investment, the UK’s development finance institution and impact investor. This marks a significant milestone in CureBay’s journey to build India’s trust infrastructure for rural health by driving equity, access, and innovation across underserved geographies.  Launched in 2021, CureBay has developed a scalable eClinic network powered by a best-in-class tech stack and a dedicated community workforce of trained and active Swasthya Mitras. It provides quality, accessible and affordable services for doctor consultation, diagnostics, pharmacy and tertiary care for rural households through its network of 150+ eClinics operational across Odisha and Chhattisgarh. Its preventive health programme boasts 90,000 active members with a renewal rate exceeding 60%. The latest capital infusion will be deployed to strengthen CureBay’s in-house, proprietary technology stack, expansion across India, while building the right teams to drive its next phase of growth. The company is utilising its AI and data capabilities for improving predictive care and operational efficiency and aims to expand its footprint to new states, including Jharkhand, Bihar, Uttar Pradesh and Madhya Pradesh. It will also invest in platform upgrades, proprietary algorithms and rural-first workflow automation tools that can one day be adapted for global health contexts.    ]]> https://biospectrumindia.com/news/106/26112/nit-rourkela-designs-breakthrough-ecg-lead-system-for-enhanced-diagnosis-of-atrial-arrhythmias.html https://biospectrumindia.com/news/106/26112/nit-rourkela-designs-breakthrough-ecg-lead-system-for-enhanced-diagnosis-of-atrial-arrhythmias.html Thu, 15 May 2025 00:00:00 +0530 Researchers at National Institute of Technology (NIT) Rourkela, Odisha, have developed an effective upgrade to Electrocardiography (ECG), one of the most commonly used techniques to monitor heart activity. This new system helps in easily detecting subtle electrical signals from the upper chambers of the heart, which are often too indistinct to be seen clearly in regular ECGs. These signals play a key role in identifying abnormal heart rhythms that can lead to serious conditions such as atrial fibrillation which can further lead to stroke. Irregular heart rhythms, or arrhythmias, are responsible for a large number of cardiac-related deaths around the world. Irregular heart rhythm in the heart’s upper chambers, known as atrial arrhythmias, are among the most common, especially in patients who have been hospitalised. Identifying these arrhythmias in early state can help doctors begin timely treatment and prevent complications. Detecting atrial arrhythmias can sometimes be difficult, particularly in busy clinical settings or with low-cost monitoring equipment. To address this challenge, NIT Rourkela research team has designed a novel lead placement system called the Atrial Lead System (ALS). In an ECG, leads refer to specific patterns of electrical measurement created by placing electrodes on different parts of the body. Lead placement involves positioning these electrodes to capture clear signals from the heart. The ALS uses a modified arrangement to improve how electrical activity from the atria is recorded. By strengthening these signals, especially the P-wave, the system helps improve the accuracy of arrhythmia detection, both by doctors and by computer-based diagnostic tools. One of the most promising aspects of this work is that it requires no change to the ECG machine itself. The innovation lies entirely in the way the leads are placed, which means the upgrade can be easily adopted in both public and private healthcare settings without additional cost. The research team has also filed a patent application for the Atrial Lead System. The project has received financial backing from the Anusandhan National Research Foundation (ANRF), Government of India. This collaborative achievement by NIT Rourkela, MIOT International, Chennai, and Jaiprakash Hospital, Rourkela, represents the impactful synergy between academic research and clinical practice, paving the way for significant advancements in cardiac diagnostics and patient care across India and beyond. ]]> https://biospectrumindia.com/news/106/25902/nit-rourkela-develops-natural-bio-ink-for-3d-bioprinting-of-bone-tissue.html https://biospectrumindia.com/news/106/25902/nit-rourkela-develops-natural-bio-ink-for-3d-bioprinting-of-bone-tissue.html Fri, 28 Mar 2025 00:00:00 +0530 A team of researchers at the National Institute of Technology (NIT) Rourkela has developed a bioink made from natural materials for 3D bioprinting of bone-like structures. This bioink is designed to address challenges in bone grafting and implants, which are commonly used to treat bone defects caused by injury or disease. The research focuses on improving existing bone repair techniques by developing a bioink that is biocompatible, easy to use, and supports bone regeneration. Bone grafting is a common method to repair damaged bones.  In this procedure, bone from another part of the body or a donor is used to replace the damaged bone. This procedure has drawbacks such as pain, limited availability, and the risk of rejection. Metal implants, such as titanium plates, are another option, but they don’t always bond well with natural bone and can cause complications over time. Both methods require surgery, and sometimes more than one procedure, for proper healing. 3D bioprinting is being explored as an alternative method for bone repair. It involves printing bone-like structures using bio-inks that contain cells and supportive biomaterials. A major challenge with the exhisting bioinks is that they require an extended preparation period in laboratory conditions before they can be implanted. The printed tissue must be maintained in a controlled environment for cells to grow and form functional bone before it can be used for treatment. This makes the process slow and difficult to implement in clinical settings. The newly developed bioink is composed of chitosan, gelatin, and nanohydroxyapatite, all of which are biocompatible and commonly used in biomedical applications.  Supported by funding from the Department of Health Research (DHR), Government of India, this bioink has potential applications in a range of clinical settings. It can be used to treat large bone defects caused by accidents, infections, or surgeries by supporting natural bone growth. It is particularly useful in reconstructive surgeries for the skull and face, where precise bone repair is necessary. The team now plans to test the developed bioinks in suitable animal models and develop a scalable production process in a Good Manufacturing Practices facility for clinical trials. To facilitate commercialisation, the researchers have also established a startup, Quixotix Bioprinting. ]]> https://biospectrumindia.com/news/106/25831/nit-rourkela-introduces-bio-based-system-to-combat-pharmaceutical-contaminants-in-water.html https://biospectrumindia.com/news/106/25831/nit-rourkela-introduces-bio-based-system-to-combat-pharmaceutical-contaminants-in-water.html Fri, 14 Mar 2025 00:00:00 +0530 Researchers at National Institute of Technology (NIT) Rourkela have developed a process to remove pharmaceutical pollutants from wastewater. The two-stage process combines adsorption and biodegradation to tackle a wide range of pharmaceutical compounds, including antibiotics, non-steroidal anti-inflammatory drugs (NSIDs), and synthetic dyes. Pharmaceutically active compounds (PhACs) have become contaminants of emerging concern due to their bioaccumulation and biomagnification through the food chain, posing significant risks to humans and aquatic organisms even at trace concentrations.  As per the research at NIT, in the first stage, the antibiotics are captured using biochar adsorbents derived from roasted coco peat and rice straw. This step significantly reduces antibiotic contamination before the biological treatment phase. The second stage employs a specialised bacterial group, including Klebsiella and Pseudomonas strains, to break down residual pharmaceutical compounds such as diclofenac, paracetamol, and synthetic dyes. When tested on synthetic wastewater containing a mix of NSAIDs, antibiotics, and pharmaceutical dyes, the system demonstrated excellent removal efficiencies. Biodegradation efficiency of pharmaceutical dyes and painkillers was more than 95 %. The biochar adsorption process also proved highly effective, removing over 99.5% of antibiotics from the water. Speaking about the significance of the research, Prof. Angana Sarkar, Associate Professor, Department of Biotechnology & Medical Engineering, NIT Rourkela, said, “The process protects biodegrading bacteria, minimises toxic byproducts, and enhances the eco-friendly management of pharmaceutical contaminants. The treatment costs about Rs. 2.6 per liter and it can be further reduced by process optimisation and integrating this system as a tertiary step in existing treatments.” The researchers suggest that this process is nontoxic, sustainable, and cost effective that can be scaled up in near future in collaboration with the pharmaceutical industries. The system, demonstrated with model pharmaceutical compounds, can be applied to other molecules with similar structures. Further treatment through standard wastewater treatment eliminates the need for additional stages for bacteria and solid residue removal. This project was funded by Science and Engineering Research Board (Under IMPRINT-2: Impacting Research Innovation and Technology, Government of India Scheme) and research work was conducted in collaboration with Cadila Pharmaceutical Ltd., Ahmedabad. ]]> https://biospectrumindia.com/news/106/25738/nit-rourkela-develops-ai-powered-model-to-improve-blood-sugar-predictions-for-diabetes-management.html https://biospectrumindia.com/news/106/25738/nit-rourkela-develops-ai-powered-model-to-improve-blood-sugar-predictions-for-diabetes-management.html Tue, 25 Feb 2025 00:00:00 +0530 A research team at National Institute of Technology (NIT) Rourkela has developed a new artificial intelligence (AI)-driven approach to improve blood sugar predictions for people with diabetes. The research presents a machine-learning model that enhances the accuracy of blood glucose level prediction, helping individuals and healthcare providers make better and personalised treatment decisions.  Managing diabetes can be difficult due to a lack of specialists, unequal access to healthcare, low medication adherence, and poor self-care. These challenges make it harder for patients to keep their blood sugar levels under control, increasing the risk of serious health problems. New digital health technologies, especially those that use Artificial Intelligence (AI), offer a way to improve diabetes care and reduce costs. Machine learning (ML) has been used in many areas of diabetes research, from basic studies to predictive tools that can help doctors and patients make better and timely decisions. However, AI learning models, especially predictive AI models, have a few drawbacks. Many of these models work like a “black box,” meaning their predictions are difficult to understand. This lack of transparency makes it hard for doctors and patients to fully trust them. Furthermore, traditional models, such as statistical forecasting methods or basic neural networks, often fail to recognise long-term glucose fluctuations and require complex fine-tuning. The researchers at NIT Rourkela focused on improving glucose forecasting using deep learning techniques. Their approach incorporates a specialised AI model that learns from past blood sugar trends and predicts future levels more accurately than existing methods. Unlike traditional forecasting models, which often struggle with long-term trends and require manual adjustments, this model processes glucose data automatically, identifying key patterns and making precise predictions.  In the long run, this AI-driven approach has the potential to enhance diabetes care through various applications. It could be integrated into smart insulin pumps to automate insulin delivery, incorporated into mobile health apps for real-time glucose tracking, or used in clinical settings to support doctors in making personalised treatment plans. Currently, the researchers are planning on testing the developed technology through extensive clinical trials at hospitals, in collaboration with senior diabetologists in Odisha. ]]> https://biospectrumindia.com/news/106/25535/odisha-launches-opdc-sets-sights-on-becoming-pharma-powerhouse.html https://biospectrumindia.com/news/106/25535/odisha-launches-opdc-sets-sights-on-becoming-pharma-powerhouse.html Thu, 09 Jan 2025 00:00:00 +0530 Odisha has unveiled a comprehensive strategic plan by setting up the Odisha Pharmaceutical Development Cell (OPDC). Operating under the direct supervision of the Chief Minister’s Office (CMO) and chaired by the Chief Secretary, OPDC aims to attract international investments, foster innovation, and transform the state into a pharmaceutical hub. “Mamina Patnaik, Odisha State Drugs Controller, has been appointed as the Nodal Officer and Convener of OPDC and Drugs Inspector Chandan Kumar Giri as the Coordinator of OPDC, underscoring the state’s commitment to structured leadership in the sector. The OPDC will serve as a bridge between government and investors, driving collaborations, Special Economic Zone (SEZ) developments, and spearheading the Odisha Pharmaceutical Policy 2025,” a senior official associated with the development stated. Under Chief Minister Mohan Charan Majhi’s guidance, Odisha aligns with Prime Minister Narendra Modi’s vision of making India the "Pharmacy of the World." Key milestones include the inauguration of the Central Drugs Testing Laboratory (CDTL) and the establishment of a Sub-Zonal Office of the Central Drugs Standard Control Organisation (CDSCO) in Bhubaneswar, solidifying the state’s regulatory and testing infrastructure. “Odisha’s resilience during  COVID-19 highlighted our dedication to the nation. With OPDC, we are creating opportunities for our youth while contributing to global healthcare, positioning our state as the pharmaceutical hub of Eastern India”, the CMO maintained.  The Odisha Pharmaceutical Policy 2025, currently under development, will focus on investment incentives, research and development (R&D) support, and skill development initiatives. A world-class Pharmaceutical SEZ is also being planned in the Khurdha-Balasore corridor, to create over 500,000 jobs by 2036 through skill enhancement and sustainable industrial growth. The state plans to attract Rs 50,000 crore in investments, with the upcoming Pharmaceutical CEO Conclave serving as a key platform to engage national and international pharmaceutical giants.    ]]> https://biospectrumindia.com/news/106/24107/odisha-govt-approves-biotechnology-policy-2024-to-enhance-state-ecosystem.html https://biospectrumindia.com/news/106/24107/odisha-govt-approves-biotechnology-policy-2024-to-enhance-state-ecosystem.html Wed, 24 Jan 2024 00:00:00 +0530 The government of Odisha has approved the Biotechnology Policy 2024 to create a flourishing ecosystem for the biotech industry. This will further promote higher education, research & infrastructure development in the sector and strengthen the supportive ecosystem for innovation, incubation, investment, income & impact to build enterprises. Association of Biotechnology Led Enterprises (ABLE) has provided valuable inputs in formulating an industry friendly and futuristic policy document. The policy provides support for development of biotech parks promoted by state agencies or private sectors. Biotech units shall be provided capital investment subsidy on actual investment in plant and machinery. Soft loan assistance will be provided to large & mega biotech units operating in the state for setting up production units in key biotech areas using high end technologies. Eligible biotech startups will be provided with financial assistance for showcasing their products or technologies in national or international events. The government will also constitute an Odisha Biotech Vision Group (OBVG) to act as a think tank and advisory body on diverse policy related issues. ]]> https://biospectrumindia.com/news/106/24062/skye-air-partners-with-regional-leprosy-training-research-institute-in-odisha.html https://biospectrumindia.com/news/106/24062/skye-air-partners-with-regional-leprosy-training-research-institute-in-odisha.html Fri, 12 Jan 2024 00:00:00 +0530 In a key development spearheaded by the Ministry of Health and Family Welfare, Delhi-based company Skye Air has secured a major mandate to enhance healthcare accessibility in the Eastern region. The competitive tender process led to Skye Air's collaboration with the Regional Leprosy Training Research Institute in Aska, focusing on healthcare advancements. Skye Air emerged as the preferred choice after a rigorous evaluation that included notable competitors such as TSAW, TechEagle and RedWing. Skye Air expertise positioned them to address healthcare challenges, enhance infrastructure, and elevate care standards for Eastern state communities. With this mandate, Skye Air will partner with the Regional Leprosy Training Research Institute in Aska to employ innovative strategies and advanced technologies. The goal is to ensure the timely and efficient delivery of essential medical supplies, diagnostics, and emergency services to remote and underserved areas. The collaboration marks a significant leap forward in healthcare accessibility and delivery, bringing together Skye Air, the Ministry of Health and Family Welfare, and the Regional Leprosy Training Research Institute in Aska. Guided by a crucial initiative, the collaboration with the Regional Leprosy Training Research Institute in Aska acknowledges specific logistical challenges. Embracing drone technology will revolutionise healthcare delivery, ensuring rapid transport of essential supplies used in healthcare. This strategic use of drones addresses regional healthcare needs, fostering enhanced accessibility and delivery.     ]]> https://biospectrumindia.com/news/106/23848/samridh-and-redwing-launch-drone-based-healthcare-network-in-rayagada-odisha.html https://biospectrumindia.com/news/106/23848/samridh-and-redwing-launch-drone-based-healthcare-network-in-rayagada-odisha.html Fri, 17 Nov 2023 00:00:00 +0530 The SAMRIDH Healthcare Blended Finance Facility, a multi-stakeholder innovation and financing platform supported by the United States Agency for International Development (USAID) and implemented by IPE Global, in collaboration with Bengaluru-based startup, Redwing, have launched a pilot drone network to enhance accessibility and affordability of healthcare services in the Rayagada district of Odisha. This pilot programme will use Redwing’s electric hybrid drones to deliver medicine and medical equipment by air to isolated areas in Rayagada District, Odisha. Rayagada, a predominantly tribal district, faces significant challenges in accessing healthcare services.  Of the 3,234 villages in the district, more than 800 are hard to reach and more than 160 face seasonal cut-offs, isolating them for certain periods of the year.  By improving the aerial delivery of essential diagnostics, drugs, and vaccines to primary and community healthcare centers, this initiative will reduce out-of-pocket expenditures and dramatically reduce the time for testing, diagnosis, and treatment of diseases, resulting in improved healthcare delivery in the rural and tribal areas of the region. USAID/India Health Office Director Michelle Lang-Alli said, “This marks an expansion of the already successful healthcare drone model, supported by USAID and Redwing Labs, which has accelerated tuberculosis diagnostics and COVID-19 testing in other rural areas of India.” The pilot project will use Redwing’s ‘made in India’ electric hybrid Vertical Take-off and Landing (VTOL) drones.  Key collaborators on the project include the District Administration of Rayagada and the Indian Institute of Management, Ahmedabad, which will help evaluate the impact and feasibility of the initiative. ]]>